trending Market Intelligence /marketintelligence/en/news-insights/trending/XZiUuBaBus8rBspWQsmb4w2 content esgSubNav
In This List

KKR completes $1.4B acquisition of PharMerica

Blog

Industries Most and Least Impacted by COVID-19: A Market-Implied Probability of Default Perspective

Blog

Top 100 Banks: Capital Ratios Show Resilience to the Pandemic

Blog

Banking Essentials Newsletter: October Edition

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


KKR completes $1.4B acquisition of PharMerica

KKR & Co. LP completed the $1.4 billion acquisition of PharMerica Corp. via a newly formed company that counts drugstore chain Walgreens Boots Alliance Inc. as a minority investor.

PharMerica shareholders will receive $29.25 per share in cash from KKR.

The acquisition takes PharMerica private and its shares will cease trading on the NYSE before the markets opens Dec. 8.

In November, stockholders of PharMerica, a provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, approved the takeover of the company.

UBS Investment Bank and Bank of America Merrill Lynch are serving as financial advisers to PharMerica and Davis Polk & Wardwell LLP is serving as the company's legal adviser.

Simpson Thacher & Bartlett LLP and Weil Gotshal & Manges LLP are serving as legal advisers to KKR and Walgreens Boots Alliance, respectively.